Researchers developed a model using routine clinical data to identify optimal glucose-lowering therapies for patients with type 2 diabetes (T2D). Individuals receiving model-predicted optimal therapy ...

A major analysis reveals which GLP-1 drugs deliver the best results for glucose control, weight loss, and side effect profiles, offering new clarity for diabetes care decisions. Study: Efficacy and ...

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type ...

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

Henagliflozin, a popular drug prescribed for type 2 diabetes, has demonstrated potential anti-aging effects in a recent study published in Cell Reports Medicine. Subscribe to our newsletter for the ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of ...

Medicare Part D spending on diabetes drugs increased 364% from 2019 to 2023, driven by GLP-1 and SGLT-2 inhibitors. Metformin spending decreased by 5%, contrasting with the surge in other diabetes ...

Henagliflozin, a popular drug prescribed for type 2 diabetes, has demonstrated potential anti-aging effects in a recent study published in Cell Reports Medicine. Telomeres are protective caps made of ...